Overview

Sacituzumab Govitecan in Recurrent Glioblastoma

Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label single arm study. All patients will receive the investigational agent.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio